Dr. Philipp Rathert, was successful in securing research funding from the Erich and Gertrud Roggenbuck -Foundation. The grant will support a project aiming to explore novel coregulators of a histone demethylase as potential drug targets in breast cancer.
Philipp Rathert, group leader at the Biochemistry Department, is interested in the functional characterization of large chromatin complexes and chromatin regulatory networks. Different layers of cross-talk between several components of this highly complex regulatory system are emerging and misregulation of the epigenome is a feature of many different diseases, especially cancer. A central question became how proteins that act on chromatin or DNA interact with one another to switch genes on or off at the right time point to establish and maintain a healthy cellular state. Advances in our ability to characterize the dynamics and wiring of chromatin regulators, as well as the induced transcriptional output under different conditions, will substantially enhance our understanding of the dynamics of gene regulation. Therefore, the group of Philipp Rathert combines state-of-the-art functional genetic tools (RNAi or CRISPR/Cas9) with cell biology and biochemical assays.
The Erich and Gertrud Roggenbuck-Foundation promotes scientific work dealing with the causes, development and therapy of cancer and has granted over 13 million euros since its inception.